Related Experiment Video

Updated: Jul 6, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Cetuximab for colorectal cancer

Fausto Roila, Marina C Garassino, Cristina Mantica

    The New England Journal of Medicine
    |March 15, 2008
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
    08:12

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

    Published on: March 14, 2019

    Related Experiment Videos

    Last Updated: Jul 6, 2026

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
    09:29

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

    Published on: September 30, 2016

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
    08:12

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

    Published on: March 14, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

    The Lancet. Oncology·2026

    PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.

    JAMA oncology·2026

    Immune checkpoint inhibitors in resectable non-small cell lung cancer: recent successes and ongoing challenges.

    Frontiers in oncology·2026

    A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study.

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026

    Probing Cellular Activity Via Charge-Sensitive Quantum Nanoprobes.

    Advanced materials (Deerfield Beach, Fla.)·2026

    Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.

    Lung cancer (Amsterdam, Netherlands)·2025

    Syncope.

    The New England journal of medicine·2026

    Chemical Bond-Orchestrated Energy Depletion to Augment Lung Cancer Chemo-Immunotherapy.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Buddy Wire-Augmented Intravascular Lithotripsy in Refractory Calcified Coronary Lesions: A Five-Case Series.

    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

    Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment.

    Biomedical microdevices·2026

    Conservative and surgical treatment of wrist osteoarthritis: a systematic review.

    Archives of orthopaedic and trauma surgery·2026

    The pre-treatment tumor microenvironment immune status determines Bacillus Calmette-Guerin immunotherapy response in early-stage bladder cancer.

    Cancer immunology research·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us